Trulieve Q1 2026: $287M Revenue, First Profit, 280E Relief

Trulieve Cannabis Corp. has reported one of the cleanest profitability stories of the 2026 multi-state operator (MSO) earnings season, posting first-quarter revenue of $287 million, GAAP net income of $2.3 million, and a 35 percent adjusted EBITDA margin. The headline numbers reflect both operational execution and the first quarter in which Trulieve formally suspended the application of Internal Revenue Code Section 280E for the 2026 taxable year, following the rescheduling of medical cannabis to Schedule III.

For an industry where most operators have spent years explaining why otherwise-healthy operations produced GAAP losses, this quarter's print marks a milestone. Trulieve's effective tax rate dropped from 258 percent in the prior period to 87 percent in Q1 2026, freeing capital that historically vanished into nondeductible costs of doing business.

The Headline Numbers

Trulieve's Q1 2026 revenue of $287 million was split heavily toward retail, with 92 percent of the top line generated through company-owned dispensaries. GAAP gross profit landed at $170 million, translating to a 59 percent gross margin — a high reading even by limited-license medical market standards.

GAAP net income came in at $2.3 million, compared with a $33.8 million net loss in the year-ago period. Adjusted EBITDA reached $100 million for the quarter, representing a 35 percent margin on revenue. Cash flow from operations was $56 million, with free cash flow of $42 million after capital expenditures. Cash on the balance sheet ended the quarter at $353 million, giving the company meaningful room to fund operations, manage existing debt, and pursue selective expansion.

The retail mix and margin profile are reflective of Trulieve's geographic footprint, which is concentrated in limited-license states where competition is structurally constrained and prices have held up better than in more saturated adult-use markets. Florida dispensaries, Pennsylvania, and Maryland anchor the company's vertical operations and have historically delivered higher per-store productivity than the national average — Florida alone hit a record 7 billion mg of THC dispensed in 2026.

280E: The Quiet Drag That Just Lifted

To understand why a single quarter matters this much, the story has to start with Section 280E of the Internal Revenue Code. For decades, Section 280E has denied federal tax deductions to businesses that traffic in Schedule I or Schedule II controlled substances. Because adult-use and medical cannabis remained Schedule I under federal law, state-licensed cannabis operators could not deduct most ordinary business expenses — payroll, marketing, rent, depreciation — when calculating federal taxable income.

The practical effect was that cannabis companies often paid effective federal tax rates of 70 percent or more, even when their statutory rate would have been 21 percent under the standard corporate framework. Year after year, those tax payments crowded out reinvestment and made GAAP profitability nearly unreachable for many otherwise-strong operators.

In April 2026, the Trump administration's Department of Justice formally placed FDA-approved marijuana products and state-licensed medical cannabis products into Schedule III, a category shared with drugs like ketamine and Tylenol with codeine. The scheduling change was the long-awaited regulatory hook that allowed state-licensed medical operators to stop applying Section 280E and to begin deducting normal business expenses again on their federal returns.

Trulieve's decision to suspend 280E application for the 2026 taxable year is reflected in the dramatic drop in its effective tax rate — from 258 percent under the previous treatment to 87 percent in Q1 2026 — and a significant portion of the quarter's reported net income flows from that change. The company also filed applications to register 206 state-licensed medical retail locations with the Drug Enforcement Administration (DEA), the operational step that pairs with the tax change to convert Schedule III from a headline into a balance-sheet event.

What 280E Relief Does to the MSO Model

Cannabis multi-state operators have long argued that their unit economics would look unrecognizable if the federal tax burden normalized. Q1 2026 is the first quarter in which that argument can be tested in real numbers, and Trulieve's results suggest the case was at least directionally correct.

Three model effects show up in the quarter. First, the gap between adjusted EBITDA and GAAP net income narrows materially as fewer cash taxes are owed on operating income. Second, free cash flow expands, giving operators room to pay down debt, reinvest in higher-margin product lines, or return capital to shareholders. Third, the implicit cost of capital declines, because investors no longer need to discount future cash flows as aggressively for a federal tax regime that taxed gross margin rather than net income.

There are caveats. Adult-use and recreational marijuana remain Schedule I, which means 280E continues to apply to those revenue streams. For MSOs with dual licenses — operating both medical and adult-use in the same state — the result is cost-allocation complexity, with operators required to segment expenses between Schedule III medical operations and Schedule I adult-use operations for federal tax purposes. Trulieve, with its weighted exposure to medical markets, sits relatively comfortably under the new regime; companies with heavier adult-use mixes will see less dramatic benefit.

A Profitable Q1 in the Context of the MSO Cohort

Trulieve was not alone in posting a profitable Q1 2026. Major MSOs Curaleaf and Green Thumb Industries also reported profitable quarters, with both companies citing the 280E shift as a structural tailwind. The shared theme across the cohort is that operational discipline built during the 280E years — tight gross margins, rigorous expense control, capital efficiency — is now compounding into clean profitability as the federal tax overhang lifts.

For long-only investors, the shift translates into more reliable benchmarks. Adjusted EBITDA was always the favored metric in the sector precisely because GAAP results were distorted by 280E. As more of the MSO peer group moves to publish clean net income, valuation conversations can begin to incorporate price-to-earnings multiples on top of the EV/EBITDA multiples that have dominated since the industry's IPO wave.

The DEA Registration Race

The other operational story embedded in Trulieve's release is the company's filing to register 206 retail locations with the DEA. Schedule III placement is not self-executing for state-licensed medical operators; they must register with the DEA to legally handle Schedule III products under federal law. The mechanics of that registration — including security requirements, inventory tracking, and recordkeeping — are still being clarified.

Trulieve's filing volume positions the company near the front of the MSO line for completed registrations. Operators that move faster on DEA registration are likely to capture earlier branding and partnership advantages with FDA-approved cannabinoid products, which represent a separate but adjacent revenue lane created by Schedule III.

Market Reaction and Stock Context

Cannabis stocks remained volatile through May 2026, with the AdvisorShares Pure US Cannabis ETF (MSOS) trading in a tight range bounded by the realities of the broader sector — uneven adult-use pricing, ongoing wholesale price declines tracked by the U.S. Cannabis Spot Index, and lingering uncertainty around a prohibitionist lawsuit seeking to reverse the Schedule III decision. Within that environment, Trulieve's print provides a credible profitability anchor for institutional investors evaluating the sector.

Investors should remain attentive to a few risk factors. A reversal of the Schedule III decision through ongoing litigation would unwind much of the 280E benefit. Adult-use markets in California, Massachusetts, and other mature states continue to face price compression, with knock-on effects for any MSO with operating exposure there. And cannabis-specific tax interpretations remain an evolving area, with each company applying its own legal judgment to the suspension of 280E for the current taxable year.

What to Watch in Q2 2026

Three watchpoints will frame the next earnings cycle. Free cash flow durability is the first: a clean quarter following the 280E change is helpful, but multiple quarters of expanding free cash flow will be needed to anchor longer-term capital decisions. Margin trajectory under the new tax regime is the second: as operators begin returning to growth investments, the question is whether they can preserve the gross-margin profile that the Q1 print delivered. And DEA registration progress is the third: completion of state-licensed medical operator registrations is a precondition for federally legal cross-state activity in regulated medical products.

Key Takeaways

• Trulieve reported Q1 2026 revenue of $287 million, GAAP net income of $2.3 million, and adjusted EBITDA of $100 million at a 35 percent margin.
• The company suspended application of Section 280E for the 2026 taxable year, dropping its effective tax rate from 258 percent to 87 percent under Schedule III rescheduling.
• Trulieve filed DEA registration applications for 206 state-licensed medical retail locations, positioning it for early operationalization of Schedule III status.
• Profitability for the broader MSO cohort is improving as 280E relief works through earnings, though adult-use revenue remains subject to the prior tax treatment.

Trying to spot Trulieve, Curaleaf, or Green Thumb retail near you? Budpedia's cannabis dispensary directory maps verified MSO and independent locations in every legal U.S. market. For more on the rescheduling story, see our Schedule III tax-relief explainer.